Neuroprotective role of estrogen upon methamphetamine and related neurotoxins within the nigrostriatal dopaminergic system

Annals of the New York Academy of Sciences

Volumn 914, Issue , 2000, Pages 112-126

  Dluzen, Dean E ^a   McDermott, Janet L ^a,b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Edwin Shaw Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; DOPAMINE; DOPAMINE TRANSPORTER; ESTROGEN; METHAMPHETAMINE; NEUROTOXIN; NEUROTRANSMITTER; NOMIFENSINE; STEROID HORMONE;

DOPAMINE METABOLISM; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; HUMAN; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OVARIECTOMY; REVIEW;

ANIMALIA; RODENTIA;

EID: 0033694559     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb05189.x     Document Type: Review

References (53)

1. Estrogen as a modulator of striatal dopaminergic neurotoxicity
2. Behavioural and biochemical evidence of an effect of estradiol on striatal dopamine receptors
3. Rapid stimulation of striatal dopamine synthesis by estradiol
4. Effect of estrogen on the basal ganglia
5. Estrogen rapidly induces c-jun immunoreactivity in rat striatum
6. Oestrogens and extrapyramidal system
7. The relationship of circulating estradiol to tardive dyskinesia in men and postmenopausal women
8. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice
9. Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice
10. Estrogen alters MPTP-induced neurotoxicity in female mice: Effects on striatal concentrations and release
11. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine
12. The impact of gender and estrogen on striatal dopaminergic neurotoxicity
13. Influence of sex, age and strain of MPTP-induced neurotoxicity
14. The dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in CD-1 mice are gender dependent
15. Sexual differences in sensitivity to methamphetamine toxicity
16. Influence of gonadal hormones on sexual differences in sensitivity to methamphetamine-induced neurotoxicity
17. MPTP - A model of Parkinson's disease
18. Sex related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine treatment may be related to differences in monoamine oxidase B
19. + on endogenous dopamine release from the rat corpus striatum superfused in vitro
20. Neurochemical investigation in vitro with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in preparations of rat brain
21. In vivo release of dopamine by perfusion of 1-methyl-4-phenylpyridium ion in the striatum with a microdialysis technique
22. In vitro release of tritiated monoamines from rat CNS tissue by the neurotoxic compound 1-methyl-phenyl-tetrahydropyridine
23. Estrogen as a neuromodulator of MPTP-induced neurotoxicity: Effects upon corpus striatal dopamine release
24. + in female, but not male rats
25. +: Evaluations using in vitro and in vivo techniques
26. Estradiol-17beta as an antioxidant: Some distinct features when compared with common fat-soluble antioxidants
27. Non-genomic actions of estrogens: Estrogens as antioxidants
28. 17-β Estradiol protects neurons from oxidative stress-induced cell death in vitro
29. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury and amyloid β-peptide toxicity in hippocampal neurons
30. Inhibition of lipid peroxidation by estradiol and 2-hydroxyestradiol
31. Antioxidant properties of steroids
32. Novel and potent biological antioxidants on membrane phospholipid peroxidation: 2-Hydroxy estrone and 2-hydroxy estradiol
33. Antioxidant effects of estradiol and 2-hydroxyestradiol on iron-induced lipid peroxidation of rat liver microsomes
34. +, a toxic metabolite of MPTP, by brain synaptosomes
35. + in mouse striatal membranes
36. Interactions of 1-methyl-4-phenylpyridinium ion and tyramine with a site putatively involved in the striatal vesicular release of dopamine
37. MPTP as it relates to the etiology of Parkinson's disease
38. +: Possible action at the dopamine transporter
39. Dopamine uptake blockers protect against the dopamine depleting effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum
40. Structure-activity study of the mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity II. Evaluation of the biological activity of the pyridinium metabolites formed from the monoamine oxidase-catalyzed oxidation of MPTP analogs
41. Dopamine transporter mRNA levels are high in midbrain neurons vulnerable to MPTP
42. Use of in vitro superfusion to assess the dynamics of striatal dopamine transporters: Influence of estrogen
43. Changes of rat striatal neuronal membrane morphology and steroid content during the estrous cycle
44. Attenuation of dopamine uptake in vivo following priming with estradiol benzoate
45. Inhibition of striatal dopamine transporter function by 17β-estradiol
46. Neurotransmitter transporters: Target for endocrine regulation
47. Endocrine disruption: Estrogen, androgen and the nervous system
48. Estrogen provides neuroprotection in transient forebrain ischemia through perfusion-independent mechanisms in rats
49. Aromatase expression by astrocytes after brain injury: Implications for local estrogen formation in brain repair
50. Postmenopausal estrogen use and Parkinson's disease with and without dementia
51. The effect of estrogen replacement on early Parkinson's disease